Cargando…
A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer
BACKGROUND: The clinical benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) is controversial. This study aimed to explore novel gene signature to predict outcome benefit of postoperative 5-Fu-based therapy in stage II CRC. METHODS: Gene-expression profiles of stage II CRCs from tw...
Autores principales: | Cao, Bangrong, Luo, Liping, Feng, Lin, Ma, Shiqi, Chen, Tingqing, Ren, Yuan, Zha, Xiao, Cheng, Shujun, Zhang, Kaitai, Chen, Changmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729289/ https://www.ncbi.nlm.nih.gov/pubmed/29237416 http://dx.doi.org/10.1186/s12885-017-3821-4 |
Ejemplares similares
-
ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation()()
por: Ma, Shiqi, et al.
Publicado: (2019) -
Corrigendum to “ErbB3 ligand, Heregulin1, is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation” [Neoplasia 21 (2019) 343–352]
por: Ma, Shiqi, et al.
Publicado: (2021) -
Whether Patients With Stage Ⅱ/Ⅲ Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data
por: Zha, Sijie, et al.
Publicado: (2022) -
Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022) -
An EV-Associated Gene Signature Correlates with Hypoxic Microenvironment and Predicts Recurrence in Lung Adenocarcinoma
por: Cao, Bangrong, et al.
Publicado: (2019)